Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Q&A: Robyn Guymer highlights risk factors of intermediate AMD | Ophthalmology Times
Photo of Robyn Guymer at EURETINA 2025 in Paris, France Professor Robyn Guymer from the University of Melbourne discussed intermediate age-related macular degeneration (AMD) at the 2025 EURETINA meeting. She explored risk factors for disease progression, focusing on optical coherence…
iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy | Ophthalmology Times
iVeena Delivery Systems has been awarded a $2 million phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will help to advance development of novel topical eye…
Christine Kay, MD, on the 152-week results of the RESTORE study for retinitis pigmentosa | Ophthalmology Times
Christine Kay, MD, a vitreoretinal surgeon and IRD specialist from Gainesville, Florida, presented the results of the RESTORE trial for MCO-010 optogenetic therapy for retinitis pigmentosa. The trial was a 152-week analysis of a novel gene therapy targeting bipolar cells.…
Investigators share positive results of DAVIO 2 trial at EURETINA 2025 | Ophthalmology Times
(Image credit: AdobeStock/THANANIT) EYP-1901, known as the vorolanib intravitreal insert, was highlighted at the EURETINA 2025 meeting, which was held in Paris, France. In 2 presentations, researchers shared the recent results from the DAVIO 2 clinical trial. What is EYP-1901?…
David Almeida, MD, MBA, PhD, advances ophthalmic training with near real surgical specimens | Ophthalmology Times
David Almeida, MD, MBA, PhD, highlights near real surgical systems (NRSS), providing ophthalmologists with anatomically accurate models that replicate real surgical scenarios for training, research, and device development. (Image credit: AdobeStock/Iurii) A vitreoretinal surgeon and clinician-scientist with Erie Retina Research…
Timothy Lai on the SALWEEN trial
Photo of Timothy Lai, MD, at EURETINA 2025 in Paris, France Timothy Lai, a clinical professor honorary at the Department of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong, presented the one-year data from the Salween study…
Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye
To learn more about or to register for EyeCon 2025, click here. Set against the backdrop of a scenic Florida coastline and a growing emphasis on cross-specialty collaboration in eye care, the Ophthalmology Times and Optometry Times EyeCon® 2025 conference is…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Positive topline data announced from AVONELLE-X and SALWEEN trials
(Image credit: ©pressmaster/AdobeStock) Roche recently announced new data from the AVONELLE-X and SALWEEN trials of Vabysmo (faricimab).1 These trial data were presented at the 25th European Society of Retina Specialists (EURETINA) Annual Congress held September 4-7 in Paris. Positive safety,…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…